截至2025年8月15日收盘，丽珠集团(000513)报收于40.1元，上涨1.13%，换手率1.82%，成交量10.63万 手，成交额4.24亿元。 交易信息汇总：8月15日主力资金净流入3934.0万元，而游资和散户资金分别净流出1062.13万元和 2871.87万元。 公司公告汇总：丽珠集团的JP-1366片注册上市许可申请获得受理，该药物用于治疗反流性食管 炎，并已完成Ⅲ期临床研究，证明其疗效不劣于耐信。 公司公告汇总 丽珠医药集团股份有限公司近日收到国家药品监督管理局核准签发的《受理通知书》，公司申请的JP- 1366片的境内生产药品注册获受理，受理号为CYHS2502991。JP-1366片是一款创新钾离子竞争性酸阻 滞剂（P-CAB），用于治疗反流性食管炎。该药物通过竞争性阻断H(+)、K(+)-ATP酶的K(+)通道，抑制 胃酸分泌，提升胃内pH值并长时间维持在4以上，有效解决夜间酸突破。公司启动了一项JP-1366片与耐 信在中国反流性食管炎患者中的多中心、随机、双盲、阳性平行对照的Ⅲ期临床研究，共纳入362例患 者。结果显示，JP-1366片在给药后8周内的食管黏膜愈合率非劣于耐信，并显 ...

Core Viewpoint - Lijun Group's JP-1366 tablet has received acceptance for its domestic production drug registration application, indicating progress in its development pipeline for treating gastroesophageal reflux disease [1][2] Company Announcements - Lijun Group's JP-1366 tablet registration application was accepted by the National Medical Products Administration, with a cumulative R&D investment of approximately RMB 185.21 million [1] - The company has initiated a Phase III clinical study for JP-1366, involving 362 patients, showing non-inferiority in esophageal mucosal healing rates compared to the control drug, Naisan [2] Market Performance - As of August 15, 2025, Lijun Group's stock closed at RMB 40.1, a 0.25% increase from the previous week, with a total market capitalization of RMB 36.254 billion [1] - The stock reached a weekly high of RMB 40.75 and a low of RMB 39.26, ranking 15th in the chemical pharmaceutical sector and 453rd among A-shares [1] Sales Projections - According to IQVIA data, the domestic terminal sales for P-CABs are projected to reach approximately RMB 1.248 billion in 2024, reflecting a year-on-year growth of 81.22%, with Q1 2025 sales estimated at RMB 394.35 million, up 81.63% year-on-year [2]